Announcement • Feb 20
Biodyne Co., Ltd., Annual General Meeting, Mar 23, 2026 Biodyne Co., Ltd., Annual General Meeting, Mar 23, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 8, gangnam-daero 53-gil, seocho-gu, seoul South Korea New Risk • Dec 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Revenue is less than US$5m (₩5.0b revenue, or US$3.4m). New Risk • Apr 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (₩5.3b revenue, or US$3.7m). Buy Or Sell Opportunity • Mar 31
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 28% to ₩11,550. The fair value is estimated to be ₩14,892, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.9% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 42% per annum. Earnings are also forecast to grow by 49% per annum over the same time period. Announcement • Feb 22
Biodyne Co., Ltd., Annual General Meeting, Mar 25, 2025 Biodyne Co., Ltd., Annual General Meeting, Mar 25, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 8, gangnam-daero 53-gil, seocho-gu, seoul South Korea New Risk • Nov 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Revenue is less than US$5m (₩4.2b revenue, or US$3.0m). Buy Or Sell Opportunity • Oct 28
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 24% to ₩19,620. The fair value is estimated to be ₩15,938, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Sep 27
Now 34% overvalued after recent price rise Over the last 90 days, the stock has risen 47% to ₩21,350. The fair value is estimated to be ₩15,919, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Aug 05
Now 22% undervalued Over the last 90 days, the stock has risen 39% to ₩12,570. The fair value is estimated to be ₩16,146, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Jul 15
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 100% to ₩16,900. The fair value is estimated to be ₩14,031, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Jun 12
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 35% to ₩15,500. The fair value is estimated to be ₩12,661, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last 3 years. Meanwhile, the company became loss making. New Risk • Mar 21
New major risk - Revenue and earnings growth Revenue has declined by 67% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 67% over the past year. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (₩4.1b revenue, or US$3.1m). Valuation Update With 7 Day Price Move • Mar 20
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩10,050, the stock trades at a trailing P/E ratio of 63.8x. Average trailing P/E is 16x in the Medical Equipment industry in South Korea. Total loss to shareholders of 21% over the past three years. Valuation Update With 7 Day Price Move • Feb 16
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩52,600, the stock trades at a trailing P/E ratio of 66.8x. Average trailing P/E is 17x in the Medical Equipment industry in South Korea. Total returns to shareholders of 108% over the past year. New Risk • Jan 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change). Valuation Update With 7 Day Price Move • Jan 18
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩56,500, the stock trades at a trailing P/E ratio of 71.7x. Average trailing P/E is 17x in the Medical Equipment industry in South Korea. Total returns to shareholders of 124% over the past year. Valuation Update With 7 Day Price Move • Dec 22
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₩61,500, the stock trades at a trailing P/E ratio of 78.1x. Average trailing P/E is 17x in the Medical Equipment industry in South Korea. Total returns to shareholders of 180% over the past year. Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩54,800, the stock trades at a trailing P/E ratio of 61.9x. Average trailing P/E is 17x in the Medical Equipment industry in South Korea. Total returns to shareholders of 199% over the past year. Valuation Update With 7 Day Price Move • Oct 20
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩45,800, the stock trades at a trailing P/E ratio of 51.7x. Average trailing P/E is 17x in the Medical Equipment industry in South Korea. Total returns to shareholders of 157% over the past year. Valuation Update With 7 Day Price Move • Sep 18
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩62,400, the stock trades at a trailing P/E ratio of 70.4x. Average trailing P/E is 18x in the Medical Equipment industry in South Korea. Total returns to shareholders of 129% over the past year. Valuation Update With 7 Day Price Move • Aug 24
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₩70,600, the stock trades at a trailing P/E ratio of 74.8x. Average trailing P/E is 18x in the Medical Equipment industry in South Korea. Total returns to shareholders of 151% over the past year. Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩51,600, the stock trades at a trailing P/E ratio of 54.7x. Average trailing P/E is 18x in the Medical Equipment industry in South Korea. Total returns to shareholders of 82% over the past year. Valuation Update With 7 Day Price Move • Apr 28
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩36,000, the stock trades at a trailing P/E ratio of 39.6x. Average trailing P/E is 17x in the Medical Equipment industry in South Korea. Total returns to shareholders of 31% over the past year.